Pro-immunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy [B16-OVA treated with MEKi, in vitro]
Ontology highlight
ABSTRACT: Pro-immunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy [B16-OVA treated with MEKi, in vitro]
PROVIDER: PRJNA602904 | ENA |
REPOSITORIES: ENA
ACCESS DATA